Evidence map›Paper›PMID 29531634›Full record

ReviewBiomicrofluidics2018

Dielectrophoresis-based microfluidic platforms for cancer diagnostics.

Jun Yuan Chan, Aminuddin Bin Ahmad Kayani, Mohd Anuar Md Ali, Chee Kuang Kok, Burhanuddin Yeop Majlis, Susan Ling Ling Hoe, Marini Marzuki, Alan Soo-Beng Khoo, Kostya Ken Ostrikov, Md Ataur Rahman and 1 more

Abstract readReview
In one paragraph

Review in Biomicrofluidics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Liquid biopsy: one cell at a time.NPJ precision oncology · 2019
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jun Yuan ChanCenter for Advanced Materials and Green Technology, Multimedia University, 75450 Melaka, Malaysia.ORCID 0000-0002-2700-7064
Aminuddin Bin Ahmad KayaniORCID 0000-0003-1841-1716
Mohd Anuar Md AliInstitute of Microengineering and Nanoelectronics, Universiti Kebangsaan Malaysia, Bangi, 43600 Selangor, Malaysia.ORCID 0000-0003-4772-7613
Chee Kuang KokCenter for Advanced Materials and Green Technology, Multimedia University, 75450 Melaka, Malaysia.ORCID 0000-0003-2529-3447
Burhanuddin Yeop MajlisInstitute of Microengineering and Nanoelectronics, Universiti Kebangsaan Malaysia, Bangi, 43600 Selangor, Malaysia.
Susan Ling Ling HoeMolecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, 50588 Kuala Lumpur, Malaysia.ORCID 0000-0002-5670-714X
Marini MarzukiMolecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, 50588 Kuala Lumpur, Malaysia.ORCID 0000-0002-6992-8590
Alan Soo-Beng KhooORCID 0000-0002-8268-5271
Kostya Ken Ostrikov
Md Ataur RahmanFunctional Materials and Microsystems Research Group, Micro Nano Research Facility, RMIT University, Melbourne, Victoria 3001, Australia.
Sharath SriramFunctional Materials and Microsystems Research Group, Micro Nano Research Facility, RMIT University, Melbourne, Victoria 3001, Australia.ORCID 0000-0002-8365-7504

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent advancement of dielectrophoresis (DEP)-enabled microfluidic platforms is opening new opportunities for potential use in cancer disease diagnostics. DEP is advantageous because of its specificity, low cost, small sample volume requirement, and tuneable property for microfluidic platforms. These intrinsic advantages have made it especially suitable for developing microfluidic cancer diagnostic platforms. This review focuses on a comprehensive analysis of the recent developments of DEP enabled microfluidic platforms sorted according to the target cancer cell. Each study is critically analyzed, and the features of each platform, the performance, added functionality for clinical use, and the types of samples, used are discussed. We address the novelty of the techniques, strategies, and design configuration used in improving on existing technologies or previous studies. A summary of comparing the developmental extent of each study is made, and we conclude with a treatment of future trends and a brief summary.

Identifiers

PMID29531634
PMCPMC5825230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.